Literature DB >> 15670788

SNPs and haplotypes in the S100B gene reveal association with schizophrenia.

Jixia Liu1, Yongyong Shi, Junxia Tang, Tingwei Guo, Xiuxia Li, Yifeng Yang, Qingying Chen, Xinzhi Zhao, Guang He, Guoyin Feng, Niufan Gu, Shaomin Zhu, Huijun Liu, Lin He.   

Abstract

The S100B gene locates in 21q22.3 and produces neurotrophin mainly in astrocytes of CNS which can act as an extensive marker of glial cell integrity. The synaptic destabilization hypothesis (GGF/SD) suggests that the functional deficiency of growth factors like S100B is involved in the etiology of schizophrenia and the S100B serum concentration is reported to be significantly increased in patients with acute schizophrenia and decreased in chronic schizophrenia patients. To validate the association between S100B and schizophrenia, 384 cases and 401 controls, all Chinese Han subjects, were recruited. Four SNPs V1 (-960C>G), V2 (-111C>T), V3 (2757C>G, rs1051169), and V4 (5748C>T, rs9722) were studied. And haplotype V3-V4 (G-C) showed a significant association with schizophrenia. Our study showed an association between schizophrenia and a possible susceptible haplotype V3-V4 (G-C) which possesses a genetic tendency for increased S100B expression. Our results suggest that S100B could be a susceptible gene for schizophrenia and provide indirect evidence for the GGF/SD hypothesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670788     DOI: 10.1016/j.bbrc.2004.12.175

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

Review 2.  Recent progress in the research field of neuropharmacology in China.

Authors:  Jin Li
Journal:  Cell Mol Neurobiol       Date:  2008-02-01       Impact factor: 5.046

3.  S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum.

Authors:  Johann Steiner; Andrea Schmitt; Matthias L Schroeter; Bernhard Bogerts; Peter Falkai; Christoph W Turck; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02-07       Impact factor: 5.270

Review 4.  Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.

Authors:  Meng Xia; Sofya Abazyan; Yan Jouroukhin; Mikhail Pletnikov
Journal:  Schizophr Res       Date:  2014-11-20       Impact factor: 4.939

5.  S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance.

Authors:  Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-10

6.  S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond.

Authors:  Guglielmo Sorci; Roberta Bianchi; Francesca Riuzzi; Claudia Tubaro; Cataldo Arcuri; Ileana Giambanco; Rosario Donato
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-18

Review 7.  Genetics of developmental dyslexia.

Authors:  Thomas S Scerri; Gerd Schulte-Körne
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-29       Impact factor: 4.785

Review 8.  Emerging role of S100B protein implication in Parkinson's disease pathogenesis.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Cell Mol Life Sci       Date:  2020-10-14       Impact factor: 9.261

Review 9.  Schizophrenia and epilepsy: is there a shared susceptibility?

Authors:  Nicola G Cascella; David J Schretlen; Akira Sawa
Journal:  Neurosci Res       Date:  2009-04       Impact factor: 3.304

10.  Variation in Candidate Traumatic Brain Injury Biomarker Genes Are Associated with Gross Neurological Outcomes after Severe Traumatic Brain Injury.

Authors:  Nicole D Osier; Yvette P Conley; David O Okonkwo; Ava M Puccio
Journal:  J Neurotrauma       Date:  2018-09-14       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.